New research indicates that people who stop using popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end conventional lifestyle plans.
Findings released in a major health publication shows that while obese people often shed about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Individuals using these drugs need to be informed of the potential of quick weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to starting mass in about one and a half years.
Analyzing Treatments
The study, which examined dozens of trials involving thousands of patients, contrasted the effects of these new drugs with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone typically experience a more gradual creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Regain
Experts believe the mechanism of the injections accounts for the accelerated rebound.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its endogenous GLP-1, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
Health authorities suggest the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes.
Professionals contend that, considering the significant potential of weight regain, the therapy is often life-long.
This perspective is supported by drug manufacturers, who say that the findings "highlight the long-term character of obesity," similar to managing diseases like high blood pressure.
User Experiences
Users who have come off the medication describe a sudden return of hunger.
"It felt as if a switch that goes on and I was suddenly ravenous," said an individual.
The struggle is worsened if patients have not adopted lasting dietary or behavioural changes during treatment.
Growing Interest
Survey data suggest that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is higher among women than men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, clinicians stress that while GLP-1 drugs are effective tools for shedding pounds, they are not a standalone fix and maintained weight loss relies on ongoing lifestyle management.
